A lotion study for people with Netherton syndrome
Part of Genetic & congenital, Skin clinical trials.
This trial tests a lotion called QRX003 for Netherton syndrome, a rare skin condition. It aims to see if the lotion is safe and helpful for managing symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 years or older.
- If you are a woman who could become pregnant, you must use birth control during the study and for 3 months after.
- You have been diagnosed with Netherton syndrome, or you agree to genetic testing to confirm it.
- You are generally healthy and do not have other medical conditions that could affect the trial results.
- Your current treatment for Netherton syndrome has been steady and is expected to stay the same during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at “skin and blood biomarkers,” meaning measurable signs in the body, in people with ichthyosis to better understand the condition. It may help researchers find ways to track disease activity and evaluate future treatments.
This trial tests a prescription lotion (QRX003) to see if it is safe and helpful for people with Netherton syndrome. Because the study checks skin symptoms on certain body areas and closely controls other treatments, it may be best for patients who can keep their current regimen stable.
This study tests a new lotion (QRX003) designed to treat Netherton Syndrome, a rare genetic skin condition. The lotion is applied to affected skin areas to see if it can reduce symptoms and improve skin health.
This trial tests a new drug called BCX17725 in people with Netherton syndrome to see if it is safe and how the body handles it. It may help by reducing skin symptoms like redness and scaling.
This study looks at the bacteria on the skin and in the gut of people with Netherton syndrome, a condition that affects the skin barrier and often causes allergies. It also compares these findings to healthy volunteers to understand how the microbiome might be different.
This study tests if a new drug called nemolizumab can help reduce itch in women with lichen sclerosus (LS) in the genital area. Participants must have tried topical steroids before.
Hear when a new Netherton Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.